Compare BioNTech SE - ADR (BNTX) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs JPMorgan Diversified Return International Eqty ETF — how do they compare? BioNTech SE - ADR trades at $89.8 (market cap $22.86B), while JPMorgan Diversified Return International Eqty ETF trades at $73.33. The key difference: JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | JPIN | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | — |
52-Week High | $119.34 | $76.96 |
52-Week Low | $83.89 | $63.14 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
JPIN trades at $72.785, down 0.78% on the day, with technical indicators showing a neutral to bearish bias. The stock faces resistance near $73 and support at $72. Recent corporate actions include a declared dividend of $0.91 scheduled for June 2026. Market sentiment remains mixed, with oscillators neutral and moving averages signaling bearish pressure.
The outlook for JPIN is cautious due to weak technical momentum and limited fundamental data availability. Key risks include market volatility and reliance on international equity performance. Investors should monitor upcoming financial disclosures for clarity on valuation and profitability metrics to assess long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
